Which statement best describes the sponsor's responsibilities for the investigational product?

• A. The sponsor should ensure that the investigational product(s) is characterized as appropriate to the stage of development of the product(s), is manufactured in accordance with any applicable GMP, and is coded and labelled in a manner that protects the blinding, if applicable. In addition, the labelling should comply with applicable regulatory requirement(s)
• B. The IP must be marketed to the general public.
• C. The IP labeling should ignore regulatory requirements.
• D. The IP must be stored at extreme temperatures only.

Answer: (A)

The main idea is that the sponsor is responsible for ensuring the investigational product is handled with quality and integrity throughout the trial. This means the IP must be characterized appropriately for where the product is in development, so its identity, strength, quality, and stability are clear. It should be manufactured in accordance with GMP to guarantee consistent quality and traceability. It should be coded and labeled in a way that preserves blinding when the study design requires it, and the labeling must comply with applicable regulatory requirements to provide accurate, essential information to investigators and participants.

Other options miss key safeguards: marketing the IP to the general public isn’t appropriate for an investigational product; labeling cannot ignore regulatory requirements; and storage needs depend on the product’s stability, not solely extreme temperatures.